Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2007

Nventa Issued Patent that Covers Fusion Protein Therapeutics for HPV-related Diseases

  • Nventa Biopharmaceuticals was issued a patent for compositions and methods for inducing or enhancing immune responses to a human papillomavirus (HPV) antigen with or without the use of an adjuvant. The company's CoVal™ HPV protein fusions are being developed to treat patients with HPV-related diseases.

    The patent provides for a method of treating a tumor expressing an HPV antigen through the administration of an effective amount of a composition comprised of an HPV antigen joined or fused to a stress protein, according to Gregory M. McKee, president and CEO of Nventa. This patent provides additional patent exclusivity for HspE7, the Company's investigational therapeutic vaccine, and future HPV fusions through February 2019.

    "The issuance of this patent protecting the use of our HPV CoVal protein fusions to treat HPV-related diseases strengthens our intellectual property portfolio and, we believe, adds further value to our HspE7 program, which is currently in Phase I clinical development," says McKee.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »